Mirum Pharmaceuticals, INC Form 4 insider transactions

Mirum Pharmaceuticals' President and COO, Peter Radovich, sold 2,631 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Mirum Pharmaceuticals CEO Christopher Peetz sold 9,108 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, received substantial equity awards including stock options, restricted stock units, and performance-based units.

Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, was granted stock options, restricted stock units, and performance restricted stock units totaling 49,900 shares on January 28, 2026.

Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkhot, was granted 49,900 derivative securities, including stock options and restricted stock units, on January 28, 2026.

Mirum Pharmaceuticals' President and COO, Peter Radovich, received substantial equity awards including stock options, restricted stock units, and performance-based units.

Mirum Pharmaceuticals CEO Christopher Peetz reported significant equity awards, including stock options, restricted stock units, and performance-based units, on January 28, 2026.

Mirum Pharmaceuticals' CFO, Eric Bjerkholt, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Mirum Pharmaceuticals' President and COO, Peter Radovich, reported the vesting of 5,750 restricted stock units and a subsequent sale of 3,143 shares to cover tax obligations.

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, acquired common stock through RSU vesting and subsequently sold shares to cover tax obligations.

Mirum Pharmaceuticals CEO Christopher Peetz reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Mirum Pharmaceuticals director Patrick J. Heron increased his indirect beneficial ownership through a merger-related share receipt and a significant share purchase.

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, sold 926 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, sold 1,822 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Mirum Pharmaceuticals' CFO, Eric Bjerkhot, exercised restricted stock units and subsequently sold a portion of the shares to cover tax obligations.

Mirum Pharmaceuticals' President and COO, Peter Radovich, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Mirum Pharmaceuticals CEO Christopher Peetz reported the vesting of 12,797 restricted stock units and a subsequent sale of 7,098 shares to cover tax obligations.

Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, reported the sale of common stock to cover tax obligations following the vesting of restricted stock units.

Mirum Pharmaceuticals Director Saira Ramasastry exercised stock options and sold an equal number of shares on January 15, 2026, under a pre-arranged 10b5-1 plan.

Mirum Pharmaceuticals CEO Christopher Peetz reported a gift of 21,070 shares of common stock to a charitable donor-advised fund.

Mirum Pharmaceuticals Director Saira Ramasastry exercised options and sold 5,000 shares of common stock for $80.00 per share under a pre-arranged 10b5-1 plan.

Mirum Pharmaceuticals director Michael G. Grey exercised options for 50,000 shares and immediately sold them for $78 per share.

Mirum Pharmaceuticals Director Saira Ramasastry exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Mirum Pharmaceuticals director Michael G. Grey exercised stock options and subsequently sold 50,000 shares of common stock for $74 per share.

Mirum Pharmaceuticals Director Michael G. Grey exercised stock options and sold 50,000 shares of common stock for $70 per share.

Mirum Pharmaceuticals CEO Christopher Peetz exercised 19,133 stock options, acquiring common stock at $19.24 per share, increasing his direct beneficial ownership.

Mirum Pharmaceuticals director Laura Brege exercised stock options and subsequently sold an equal number of shares under a pre-arranged plan.

Mirum Pharmaceuticals' CFO, Eric Bjerkholt, reported pre-scheduled transactions for September 2025, including RSU vesting and a subsequent share sale for tax obligations.

Mirum Pharmaceuticals Director Saira Ramasastry exercised stock options and immediately sold the resulting common stock for a significant gain.